22
Participants
Start Date
October 31, 2008
Primary Completion Date
September 30, 2014
Study Completion Date
April 30, 2015
SOM230
Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
RAD001
Given orally once a day
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Collaborators (1)
Beth Israel Deaconess Medical Center
OTHER
Brigham and Women's Hospital
OTHER
Massachusetts General Hospital
OTHER
Novartis
INDUSTRY
Dana-Farber Cancer Institute
OTHER